Senate Hearing on Prescription Drug Costs and Delivery Systems
January 1, 2019
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
The hearing provides insight into the complex supply chain of prescription drugs, which directly influences the out-of-pocket costs for patients and the overall affordability of healthcare services.
Potentially affected actors named in the source documents. Mention is not a position.
Patients
The drug delivery system discussed in the hearing determines the final out-of-pocket costs patients pay for prescription medications.
Pharmaceutical Industry
Industry representatives provided testimony regarding their roles in the drug supply chain and the factors influencing drug pricing.
Last recorded activity January 1, 2019.
Next step not available in the current record.
Summary
Key Facts
- The Senate Committee on Health, Education, Labor, and Pensions held a hearing on October 17, 2017, to investigate the prescription drug delivery system.
- The hearing focused on identifying factors within the supply chain that contribute to the final price paid by patients.
- Testimony was provided by representatives from pharmaceutical manufacturers, generic drug associations, drug distributors, pharmacy benefit managers, and pharmacists.
- The document includes formal written statements and summary statements from five industry organizations.
- The committee members submitted additional questions for the record to the witnesses following the hearing.
Frequently Asked Questions
What was the purpose of this hearing?
Who testified at the hearing?
Why It Matters
The hearing provides insight into the complex supply chain of prescription drugs, which directly influences the out-of-pocket costs for patients and the overall affordability of healthcare services.
News Coverage
Sponsors
Show 2 more sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Supply Chain Transparency
The hearing highlights a shift toward examining the entire drug supply chain rather than just manufacturer pricing to understand patient costs.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools